Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
CA 2389415 A1 · Owner: Milford, Edgar L. · Inventors: Milford, Edgar L.; Utku, Nalan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described are generally immune response cDNA TZap7/A TZap7/B and TZap7 , polynucleotides encoding novel proteins involved in modulation of immune responses and antibodies recognizing said proteins. Furthermore vectors , comprising the aforementioned polynucleotides and host cells transformed therewith as well as their use in the production of the above-defined proteins are described. Additionally, pharmaceutical and diagnostic compositions are provided comprising any one of the afore-described polynucleotides vectors, proteins, or antibodies. Furthermore methods and uses for modulating immune responses through the novel TZap protein as well as pharmaceutical compositions comprising …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 30, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 30, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 30, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.